ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,148.39
0.40%
US Tech 100
17,474.80
0.32%
Dow Jones
38,848.09
0.45%
Brent Oil
83.21
0.10%
Bitcoin
63,581.41
-0.67%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Nextensa SA (NEXTA) Quote

Nextensa SA

Nextensa SA (NEXTA)

EU
47.75
0.35
( 0.74% )
Updated: 09:14:20
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
47.75
Bid
47.70
Ask
48.20
Volume
1,444
47.45 Day's Range 48.50
42.40 52 Week Range 50.90
Market Cap
485.097M
Previous Close
47.40
Open
47.45
Last Trade
53
@
47.75
Last Trade Time
09:07:33
Financial Volume
-
VWAP
-
Average Volume (3m)
1,383
Shares Outstanding
10,002,000
Dividend Yield
-
PE Ratio
19.81
Earnings Per Share (EPS)
2.45
Revenue
127.18M
Net Profit
24.49M

About Nextensa SA

Sector
Real Estate Investment Trust
Industry
Real Estate Investment Trust
Website
www.nextensa.eu
Headquarters
Brussels, Brussels-capital Region, Bel
Founded
1970
Nextensa SA is listed in the Real Estate Investment Trust sector of the Euronext with ticker NEXTA. The last closing price for Nextensa was 47.40 €. Over the last year, Nextensa shares have traded in a share price range of 42.40 € to 50.90 €.

Nextensa currently has 10,002,000 shares outstanding. The market capitalization of Nextensa is 485.10 € million. Nextensa has a price to earnings ratio (PE ratio) of 19.81.

NEXTA Latest News

More News

Nextensa NV/SA : Information on the total number of voting rights and shares

Nextensa NV/SA : Information on the total number of voting rights and shares PRESS RELEASE REGULATED INFORMATIONBrussels, 30 April 2024 17h40          Nextensa NV/SA : Information on the...

April 30 2024
GlobeNewswire Inc.

Nextensa : Convocation à l’assemblée générale ordinaire et extraordinaire des actionnaires du 21 mai 2024

Nextensa : Convocation à l’assemblée générale ordinaire et extraordinaire des actionnaires du 21 mai 2024 COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉE Bruxelles, le 11 avril 2024 17h40    ...

April 11 2024
GlobeNewswire Inc.

Nextensa: RÉSULTATS ANNUELS 2023

Nextensa: RÉSULTATS ANNUELS 2023 INFORMATION RÉGLEMENTÉEBruxelles, 21 février 2024, 17h40 NEXTENSA: RÉSULTATS ANNUELS 2023 Faits marquants IMMEUBLES DE PLACEMENT• Nextensa réalise un...

February 21 2024
GlobeNewswire Inc.

Quares Residential Investment acquiert l’immeuble résidentiel Imperial à Tour & Taxis auprès de Nextensa

Quares Residential Investment acquiert l’immeuble résidentiel Imperial à Tour & Taxis auprès de Nextensa COMMUNIQUÉ DE PRESSEBruxelles, le 2 janvier 2024, 07h30Information non-réglementée...

January 02 2024
GlobeNewswire Inc.

Nextensa: Interim results per Q3 2023

Nextensa: Interim results per Q3 2023 REGULATED INFORMATION Brussels, 20 November 2023, 5:40 PM NEXTENSA:  NOTES OF THE BOARD OF DIRECTORS ON Q3 2023 HIGHLIGHTS  • Hybrid model pays off:...

November 20 2023
GlobeNewswire Inc.

The developers Nextensa and Promobe have sold the Darwin II office building to the Luxembourg State

The developers Nextensa and Promobe have sold the Darwin II office building to the Luxembourg State PRESS RELEASEBrussels, 26 October 2023, 5:40 PMNon-regulated informationTHE DEVELOPERS...

October 26 2023
GlobeNewswire Inc.

Nextensa acquires office building Montoyer 24 in Brussels

Nextensa acquires office building Montoyer 24 in Brussels PRESS RELEASE Brussels, 22 August 2023 17h40 Non-regulated information NEXTENSA ACQUIRES OFFICE BUILDING MONTOYER 24 IN BRUSSELS...

August 22 2023
GlobeNewswire Inc.

Nextensa: Rapport financier semestriel 2023

Nextensa: Rapport financier semestriel 2023 INFORMATION RÉGLEMENTÉEBruxelles, le 17 août 202317h40NEXTENSA: RAPPORT FINANCIER SEMESTRIEL 2023FAITS MARQUANTSPour le premier semestre de...

August 17 2023
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
112.1390374331646.7548.546.7578347.31415576DE
41.252.6881720430146.548.545.65123446.45823951DE
122.24.8298572996745.5548.542.4138344.68045415DE
260.250.52631578947447.550.942.4164347.33451092DE
52-1.45-2.9471544715449.250.942.4176946.27501986DE
156-24.65-34.04696132672.479.637.05266351.81061244DE
260-24.65-34.04696132672.479.637.05266351.81061244DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.349
(0.00%)
4.07k
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.78
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.12
(0.00%)
4.31k
AACIArmada Acquisition Corporation I
$ 11.75
(0.00%)
895
AACGATA Creativity Global
$ 0.907326
(0.00%)
23
AAGRAfrican Agriculture Holdings Inc
$ 0.349
(0.00%)
4.07k
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.78
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.12
(0.00%)
4.31k
AACIArmada Acquisition Corporation I
$ 11.75
(0.00%)
895
AACGATA Creativity Global
$ 0.907326
(0.00%)
23
XBPXBP Europe Holdings Inc
$ 2.12
(0.00%)
22.53M
LYRALyra Therapeutics Inc
$ 0.75
(0.00%)
10.5M
ALLRAllarity Therapeutics Inc
$ 1.00
(0.00%)
10.34M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0409
(0.00%)
10.08M
SBFMSunshine Biopharma Inc
$ 0.84
(0.00%)
6.5M

Discussion

View Full Feed
wadegarret wadegarret 5 minutes ago
IART CC is now over- here is my view

I think the stock has been decimated to a 9 PE going forward vs the industry 20-27 PE going forward, for concern that without the Boston Factory, their earnings would go down substantially. However it appears to me, that with their present pro
Jetmek_03052 Jetmek_03052 5 minutes ago
You made this statement:

"So it appears that subject to a review, Alpine has been expelled from DtCC/NSCC as of 4/25/24." 👍️

I asked you to post a verifiable source to be able to confirm your statement. All I got was SILENCE (which really wasn't surprising).
DBMM
MED111 MED111 6 minutes ago
Winter season and road melting are no longer relevant. Drilling is over, and oil is confirmed. The next catalyst is the final report in Q2, then commercial news whatever they might be: farming out/partnership, buyout etc. Not dependent on the season. Plus news from Namibia.
EEENF
misterfishman misterfishman 6 minutes ago
lets gooooo.
AGBA
crazy horse 0 crazy horse 0 6 minutes ago
Hello buddy

GM, CH
Reyeton Reyeton 6 minutes ago
Looks like a no win for AVXL. Looks like Misleading’s days as CEO are coming to an end. Could only be good for the company though.

https://fox2now.com/business/press-releases/globenewswire/9105826/avxl-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-anavex-life-sciences-c
AVXL
EmperorVoyager30 EmperorVoyager30 6 minutes ago
10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE)
WONDER IF WE HEAR ANYTHING BACK ON THIS TODAY???
JAGX
INV4 INV4 6 minutes ago
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs

Jaguar Health, Inc.
Mon, May 6,
JAGX
ducci1 ducci1 7 minutes ago
We were just starting to learn the more advanced option strategies--Appreciated your sharing very much!!---It's a bunch of BULL/SHHHH----I'm not a Happy Camper!!!---Good Luck!!
SPY
Kreator Kreator 7 minutes ago
Stop asking for news, with your posts.
LWLG
Myth Myth 7 minutes ago
good Monday morning laugh cap !
EmperorVoyager30 EmperorVoyager30 7 minutes ago
ANIMALS AND HUMANS..... YOU MUST BE NEW......
JAGX
tedpeele tedpeele 7 minutes ago
Newcomers, most here do NOT know what they own. 33 questions they simply can't give a good answer to:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174232127

Easy peasy to explain why the market has soured on the stock since the farce of ASM 2021
ASM
Tiger Money Tiger Money 7 minutes ago
Yea I only see 4350 ish traded
VIRI
prototype_101 prototype_101 7 minutes ago
The article Synopsis Photonics Solutions posted on LinkedIn was from the PIC Magazine article by Michael Lebby here

https://www.linkedin.com/posts/synopsysphotonicsolutions_article-by-michael-lebby-ceo-lightwave-activity-7181893534705201153-QcJ2/

Synopsys reposted anoth
GFS LWLG
willpellel willpellel 7 minutes ago
Time will tell.
TONR
Chartmaster Chartmaster 8 minutes ago
C'mon jrsh, NSAV is going higher! And you know it! Chart, News, and Momentum as I say and NSAV has all 3!
NSAV
ALDRADJKD123 ALDRADJKD123 8 minutes ago
Donald Trump Demands Jack Smith Be Arrested After Document Revelation

https://www.newsweek.com/donald-trump-arrest-jack-smith-classified-documents-1897287
DJT
sharky sharky 8 minutes ago
GM all, looking forward to the news $$$


$BLEG
BLEG
uranium-pinto-beans uranium-pinto-beans 8 minutes ago
Disney price target raised to $130 from $125 at Deutsche Bank
Deutsche Bank raised the firm's price target on Disney to $130 from $125 and keeps a Buy rating on the shares. The firm increased operating income estimates to reflect Parks, Sport and Studio, partially offset by lowered direct-to-
Zardiw Zardiw 8 minutes ago
Nice!!!........... $IFUS has a great concept..........

Z
IFUS
DiscoverGold DiscoverGold 8 minutes ago
NY Gold Futures »» Weekly Summary Analysis
By: Marty Armstrong | May 4, 2024

NY Gold Futures closed today at 23086 and is trading up about 11% for the year from last year's settlement of 20718. Caution is required for this market is starting to suggest it may now decline o
GOLD
ShadowDiviner72 ShadowDiviner72 9 minutes ago
'We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs'

BENZINGA: Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet
JAGX

Your Recent History

EU
NEXTA
Nextensa
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved